[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555718":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":48,"responsibleParty":234,"collaborators":237,"id":249,"slug":250,"hasResults":251,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":251,"sex":257,"minAge":258,"maxAge":42,"enrollmentInfo":259,"targetDuration":42,"studyType":262,"phases":263,"briefSummary":265,"conditions":266,"keywords":269,"overallStatus":112,"whyStopped":42,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":280},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Apixaban","EXPERIMENTAL","Apixaban 5 mg twice a day, reduced to 2.5 mg twice a day for participants with any 2 of following criteria: age \\> 80 years, serum creatinine \\> 133 μmol\u002FL or body weight \\\u003C60 kg. Participants with severe renal failure defined as creatinine clearance 15-29 ml\u002Fmin\u002F1.73 m2, should also receive the reduced dose of 2.5 mg twice a day.",[13],"Drug: Apixaban",{"label":15,"type":16,"description":17,"interventionNames":18},"Warfarin","ACTIVE_COMPARATOR","Warfarin 2,5 mg once daily with individual dosing according to coagulation assays with an international normalized ratio (INR) goal of 2.0-3.0. Bridging with low-molecular-weight-heparin with a dose of dalteparin 200 units\u002Fkg but maximum 18 000 units or enoxaparin 150 units\u002Fkg, until therapeutic INR is recommended.",[19],"Drug: Warfarin",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","5 mg tablet twice a daily with dose reduction according to label",[9],[26],"Eliquis",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"2.5 mg tablet once daily, with individual dosing according to coagulation tests",[15],[31],"Waran",[33],{"name":34,"affiliation":35,"role":36},"Moa Simonsson, MD, PhD","Department of Medicine Solna, Karolinska Institutet","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Eva Olofsson","CONTACT","+46707780897",null,"moa.simonsson@ki.se",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Stina Smetana","+46725841182","stina.smetana@ki.se",[49,66,79,88,97,110,124,137,144,157,170,180,188,198,208,221],{"facility":50,"status":51,"city":52,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Falu lasarett","NOT_YET_RECRUITING","Falun","Sweden","SE",{"type":56,"coordinates":57},"Point",[58,59],15.62597,60.60357,{"lat":59,"lon":58},[62],{"name":63,"role":40,"phone":64,"phoneExt":42,"email":65},"Elin Falås, MD","+46 23 49 00 00","elin.falas@gmail.com",{"facility":67,"status":51,"city":68,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Sahlgrenska University hospital, Mölndal","Gothenburg",{"type":56,"coordinates":70},[71,72],11.96679,57.70716,{"lat":72,"lon":71},[75],{"name":76,"role":40,"phone":77,"phoneExt":42,"email":78},"Georgios Mourtzinis, MD, PhD","+46 31 342 10 00","georgios.mourtzinis@vgregion.se",{"facility":80,"status":51,"city":68,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"Sahlgrenska University hospital, Östra",{"type":56,"coordinates":82},[71,72],{"lat":72,"lon":71},[85],{"name":86,"role":40,"phone":77,"phoneExt":42,"email":87},"Katarina Glise-Sandblad Glise Sandblad, MD, PhD","katarina.glise.sandblad@vgregion.se",{"facility":89,"status":51,"city":68,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":90,"geoPoint":92,"contacts":93},"Sahlgrenska University hospital",{"type":56,"coordinates":91},[71,72],{"lat":72,"lon":71},[94],{"name":95,"role":40,"phone":77,"phoneExt":42,"email":96},"Annica Ravn-Fischer, MD, PhD","annica.ravn-fischer@vgregion.se",{"facility":98,"status":51,"city":99,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Linköping University hospital","Linköping",{"type":56,"coordinates":101},[102,103],15.62157,58.41086,{"lat":103,"lon":102},[106],{"name":107,"role":40,"phone":108,"phoneExt":42,"email":109},"Mats Pettersson, MD, PhD","+46 10 103 00 00","Mats.Pettersson@regionostergotland.se",{"facility":111,"status":112,"city":113,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Skånes Universitetssjukhus Lund","RECRUITING","Lund",{"type":56,"coordinates":115},[116,117],13.19321,55.70584,{"lat":117,"lon":116},[120],{"name":121,"role":40,"phone":122,"phoneExt":42,"email":123},"Josef Dankiewicz, MD, PhD","+ 46 4617 10 00","josef.dankiewicz@gmail.com",{"facility":125,"status":51,"city":126,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Skånes University hospital, Malmö","Malmö",{"type":56,"coordinates":128},[129,130],13.00073,55.60587,{"lat":130,"lon":129},[133],{"name":134,"role":40,"phone":135,"phoneExt":42,"email":136},"Helena Grauen Larsen, MD, PhD","+46 40 33 10 00","Helena.GrauenLarsen@skane.se",{"facility":138,"status":51,"city":139,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":42,"geoPoint":42,"contacts":140},"Vrinnevi hospital","Nörrköping",[141],{"name":142,"role":40,"phone":108,"phoneExt":42,"email":143},"Malgorzata Pierscinska-Jedra, MD","Malgorzata.Pierscinska-Jedra@regionostergotland.se",{"facility":145,"status":51,"city":146,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Örebro University hospital","Örebro",{"type":56,"coordinates":148},[149,150],15.2066,59.27412,{"lat":150,"lon":149},[153],{"name":154,"role":40,"phone":155,"phoneExt":42,"email":156},"Robin Gustafsson, MD, PhD","+46 19 602 10 00","robin.gustafsson@regionorebrolan.se",{"facility":158,"status":112,"city":159,"state":42,"zip":160,"country":53,"countryCode":54,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Karolinska Insitutet","Stockholm","17177",{"type":56,"coordinates":162},[163,164],18.06871,59.32938,{"lat":164,"lon":163},[167],{"name":34,"role":40,"phone":168,"phoneExt":42,"email":169},"+46707411272","moa.simonsson@regionstockholm.se",{"facility":171,"status":51,"city":159,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":172,"geoPoint":174,"contacts":175},"Danderyds hospital",{"type":56,"coordinates":173},[163,164],{"lat":164,"lon":163},[176],{"name":177,"role":40,"phone":178,"phoneExt":42,"email":179},"Mika Skeppholm","+ 46 8 123 550 00","mika.skeppholm@regionstockholm.se",{"facility":181,"status":112,"city":159,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":182,"geoPoint":184,"contacts":185},"Karolinska Univerity Hospital",{"type":56,"coordinates":183},[163,164],{"lat":164,"lon":163},[186],{"name":34,"role":40,"phone":187,"phoneExt":42,"email":43},"+46 707411272",{"facility":189,"status":51,"city":159,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":190,"geoPoint":192,"contacts":193},"Sankt Görans Hospital",{"type":56,"coordinates":191},[163,164],{"lat":164,"lon":163},[194],{"name":195,"role":40,"phone":196,"phoneExt":42,"email":197},"Emil Grönlund, MD","+46 8 587 010 00","emil.gronlund@capiostgoran.se",{"facility":199,"status":51,"city":159,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":200,"geoPoint":202,"contacts":203},"Södersjukhuset",{"type":56,"coordinates":201},[163,164],{"lat":164,"lon":163},[204],{"name":205,"role":40,"phone":206,"phoneExt":42,"email":207},"Robin Hofmann, MD, PhD","+46 8 123 610 00","robin.hofmann@regionstockholm.se",{"facility":209,"status":51,"city":210,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Uppsala Akademiska hospital","Uppsala",{"type":56,"coordinates":212},[213,214],17.63889,59.85882,{"lat":214,"lon":213},[217],{"name":218,"role":40,"phone":219,"phoneExt":42,"email":220},"Christina Christersson","+46 18 611 00 00","Christina.Christersson@medsci.uu.se",{"facility":222,"status":51,"city":223,"state":42,"zip":42,"country":53,"countryCode":54,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Västmanlands hospital, Västerås","Västerås",{"type":56,"coordinates":225},[226,227],16.55276,59.61617,{"lat":227,"lon":226},[230],{"name":231,"role":40,"phone":232,"phoneExt":42,"email":233},"Anders Nordfors, MD, PhD","+46 21 17 30 00","anders.nordfors@regionvastmanland.se",{"type":36,"investigatorFullName":235,"investigatorTitle":236,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Moa Simonsson","MD, PhD",[238,241,243,246],{"name":239,"class":240},"Karolinska Trial Alliance","INDUSTRY",{"name":242,"class":6},"Swedish Heart Lung Foundation",{"name":244,"class":245},"The Swedish Research Council","OTHER_GOV",{"name":247,"class":248},"Stockholm County Council ALF\u002FPPG","UNKNOWN","100555718","phase-4-treatment-with-apixaban-versus-warfarin-in-patients-with-left-ventricular-thrombus-after-acute-myocardial-infarction-100555718",false,"NCT06515730","Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","RandomizEd compariSOn of Apixaban Versus Warfarin in Patients With Left VEntricular Thrombus After Acute Myocardial Infarction (RESOLVE-AMI)","RESOLVE-AMI","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of signing the informed consent\n* LV thrombus confirmed on TTE\\* day 1-28 after the AMI\n* Signed informed consent\n* Criteria applicable only for female subjects: Women of childbearing potential must provide a negative pregnancy test not be breastfeeding and be willing and able to use highly effective contraception. Women of non-childbearing potential must be 1 year post-menopausal.\n\nExclusion Criteria:\n\n* Ongoing\\* treatment with anticoagulant therapy due to Mechanical heart valve prosthesis Atrial fibrillation with or without significant mitral valve stenosis Venous thromboembolism requiring anticoagulant therapy Thrombophilia requiring anticoagulant therapy Preexisting LV thrombus already treated with anticoagulant therapy Other reasons for anticoagulant therapy\n* High bleeding risk Active non-trivial bleeding Known chronic bleeding disorder Severe anemia defined as hemoglobin \\\u003C 80g\u002FL Thrombocytopenia defined as platelet count \\\u003C 80 x 10\\^9\n* Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or known hepatic insufficiency classified as Child-Pugh C or D at randomization\n* Known allergy, intolerance or hypersensitivity to either of the study interventions\n* Any contraindication for the use of an anticoagulant or listed in the local labelling for apixaban or warfarin.\n* Participation in other study investigating effects and safety of anticoagulant treatment.\n* Known current alcohol or drug abuse\n* Any other condition, as judged by the investigator, that would make the participant unsafe or unsuitable for the study or life expectancy \\\u003C 6 months","ALL","18 Years",{"count":260,"type":261},212,"ESTIMATED","INTERVENTIONAL",[264],"PHASE4","The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.",[267,268],"Left Ventricular Thrombus","Acute Myocardial Infarction",[9,270],"warfarin","2025-06-26",{"date":273,"type":274},"2025-07-01","ACTUAL",{"date":276,"type":274},"2025-04-08",{"date":278,"type":261},"2028-07-01",{"name":5,"class":6},16]